SWOG S1216

Primary Category:

Treatment Protocols

Disease Category:

Genitourinary, Prostate, Prostate Metastatic



A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer


S1216 has met its accrual goal and will permanently close to accrual effective July 15, 2017 at 11:59 p.m. Pacific.

Leave a Reply